长链非编码RNA在多发性骨髓瘤发生发展中的作用

贺玉钦; 高文; 陈文明

doi:10.3969/j.issn.1000-8179.2019.12.236

长链非编码RNA在多发性骨髓瘤发生发展中的作用

doi: 10.3969/j.issn.1000-8179.2019.12.236

贺玉钦^①,,
高文^②,
陈文明^②, ,

①.
首都医科大学附属北京朝阳医院急诊科（北京市100020）
②.
首都医科大学附属北京朝阳医院血液科（北京市100020）

基金项目:

北京市医管局（第二期）“登峰”人才培养计划项目 DFL20180301

“重大新药创制”科技重大专项项目 2018ZX09733003

详细信息

作者简介:
贺玉钦专业方向为多发性骨髓瘤的基础与临床研究。E-mail：doctorhe_2015@163.com

通讯作者:
陈文明 13910107759@163.com

计量
- 文章访问数: 77
- HTML全文浏览量: 13
- PDF下载量: 6
- 被引次数: 0
出版历程
- 收稿日期: 2019-02-27
- 修回日期: 2019-06-10
- 刊出日期: 2019-06-30

The function of long non-coding RNA in the occurrence and development of multiple myeloma

He Yuqin^{①
,},
Gao Wen^②,
Chen Wenming^{②
, ,}

①.
Department of Emergency, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China
②.
Department of Hematology, Beijing Chao-yang Hospital, Capital Medical University, Beijing 100020, China

Funds:

Beijing Hospital Authority "Deng Feng" Talents Cultivating Project DFL20180301

"Special Medicine Innovation" Scientific Special Project 2018ZX09733003

摘要

摘要: 多发性骨髓瘤（multiple myeloma，MM）为血液系统发病率位居第二位的常见恶性肿瘤，其主要特征之一是基因的异质性。长链非编码RNA（long non-coding RNA，lncRNA）的数目异常与MM的恶性度存在密切关系。伴随新的分子生物学技术的进步，如原位荧光杂交（fluorescence in situ hybridization，FISH）、高通量测序（high-throughput sequencing）、基因芯片（gene microarray）和定量聚合酶链反应（quantitative real time polymerase chain reaction，qRT-PCR）对MM的细胞遗传学异常的研究有了较大拓展。本文针对11种新发现的lncRNA来阐释MM的不同机制。lncRNA有望成为诊治MM的潜在靶点。
- 肿瘤 /
- 多发性骨髓瘤 /
- 基因异质性 /
- 长链非编码RNA
Abstract: Multiple myeloma (MM) is characterized by genetic heterogeneity and is a common secondary hematological malignancy. Many studies have revealed that variation in the number of long non-coding RNAs (lncRNAs) is related to the degree of MM malignancy. Advances in molecular biology technologies, such as fluorescence in situ hybridization, high-throughput sequencing, gene microarrays, and qRT-PCR, have furthered research into cytogenetic malfunction in MM. Eleven newly discovered lncRNAs in MM have been fully interpreted according to the different mechanisms of MM and have the potential to be promising biomarkers for MM diagnosis and therapy.
- malignancy /
- multiple myeloma /
- genetic heterogeneity /
- long non-coding RNA (lncRNA)

HTML全文

参考文献(40)

[1]	Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol, 2014, 15(12):e538-e548. doi: 10.1016/S1470-2045(14)70442-5
[2]	Ronchetti D, Agnelli L, Pietrelli A, et al. A compendium of long noncoding RNAs transcriptional fingerprint in multiple myeloma[J]. Sci Rep, 2018, 8(1):6557. doi: 10.1038/s41598-018-24701-8
[3]	Volders PJ, Verheggen K, Menschaert G, et al. An update on LNCipedia: a database for annotated human lncRNA sequences[J]. Nucleic Acids Res, 2015, 43(8):4363-4364. doi: 10.1093/nar/gkv295
[4]	Amodio N, Stamato MA, Juli G, et al. LNA-gapmer antisense oligonucleotides targeting the oncogenic lncrna MALAT1 trigger antimultiple myeloma activity by proteasome blockade[J]. Blood, 2017, 130(Suppl 1):1762-1765. http://www.bloodjournal.org/content/130/Suppl_1/1762?sso-checked=true
[5]	Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals[J]. Nature, 2009, 458(7235):223-227. doi: 10.1038/nature07672
[6]	Freedman ML, Monteiro AN, Gayther SA, et al. Principles for the postGWAS functional characterization of cancer risk loci[J]. Nat Genet, 2011, 43(6):513-518. doi: 10.1038/ng.840
[7]	Pandey GK, Mitra S, Subhash S, et al. The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation[J]. Cancer Cell, 2014, 26 (5):722-737. doi: 10.1016/j.ccell.2014.09.014
[8]	Yoon JH, Abdelmohsen K, Srikantan S, et al. LincRNA-p21 suppresses target mRNA translation[J]. Mol Cell. 2012. 47(4): 648-655. doi: 10.1016/j.molcel.2012.06.027
[9]	Nobili L, Ronchetti D, Agnelli L, et al. Long non-coding RNAs in multiplemyeloma[J]. Genes (Basel), 2018, 9(2):69-73. doi: 10.3390/genes9020069
[10]	Tripathi V, Ellis JD, Shen Z, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation[J]. Mol Cell, 2010, 39(6):925-938. doi: 10.1016/j.molcel.2010.08.011
[11]	Roy M, Liang L, Xiao X, et al. Lycorine downregulates HMGB1 to inhibit autophagy and enhances bortezomib activity in multiple myeloma[J]. Theranostics, 2016, 6(12):2209-2224. doi: 10.7150/thno.15584
[12]	Gao D, Lv AE, Li HP, et al. LncRNA MALAT-1 clevates HMGB1 to promote autophagy resulting in Inhibition of tumor cell apoptosis in multiple myeloma[J]. J Cell Biochem, 2017, 118(10):3341-3348. doi: 10.1002/jcb.25987
[13]	Liu H, Wang H, Wu B, et al. Down-regulation of long non-coding RNA MALAT1 by RNA interference inhibits proliferation and induces apoptosis in multiple myeloma[J]. Clin Exp Pharmacol Physiol, 2017, 44(10):1032-1041. doi: 10.1111/1440-1681.12804
[14]	Handa H, Kuroda Y, Kimura K, et al. Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma[J]. Br J Haematol, 2017, 179 (3):449-460. doi: 10.1111/bjh.14882
[15]	Matsumoto T, Abe M. TGF- beta- related mechanisms of bone destruction in multiple myeloma[J]. Bone, 2011, 48(1):129-134. doi: 10.1016/j.bone.2010.05.036
[16]	Ellis BC, Molloy PL, Graham LD. CRNDE: a long non-coding RNA involved in cancer, neurobiology, and development[J]. Front Genet, 2012, (3): 270. http://d.old.wanfangdata.com.cn/Periodical/zlfzyj201603004
[17]	Meng YB, He X, Huang YF, et al. Long noncoding RNA crnde promotes multiple myeloma cell growth by suppressing miR-451[J]. Oncol Res Treat, 2017, 25(7):1207-1014. doi: 10.3727/096504017X14886679715637
[18]	Haertle L, Maierhofer A, Bock J, et al. Hypermethylation of the nonimprinted maternal MEG3 and paternal MEST alleles is highly variable among normal individuals[J]. PLoS One, 2017, 12(8):e0184030. doi: 10.1371/journal.pone.0184030
[19]	Benetatos L, Dasoula A, Hatzimichael E, et al. Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma [J]. Clin Lymphoma Myeloma, 2008, 8(3):171-175. doi: 10.3816/CLM.2008.n.021
[20]	Zhuang W, Ge X, Yang S, et al. Upregulation of lncRNA MEG3 promotes osteogenic differentiation of mesenchymal stem cells from multiple myeloma patients by targeting BMP4 transcription[J]. Stem Cells, 2015, 33(6):1985-1997. doi: 10.1002/stem.1989
[21]	Wang XS, Zhang Z, Wang HC, et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma[J]. Clin Cancer Res, 2006, 12(16):4851-4858. doi: 10.1158/1078-0432.CCR-06-0134
[22]	Zhang ZS, Wang J, Zhu BQ, et al. Long noncoding RNA UCA1 promotes multiple myeloma cell growth by targeting TGF-beta[J]. Eur Rev Med Pharmacol Sci, 2018, 22(5):1374-1379. https://www.ncbi.nlm.nih.gov/pubmed/29565496
[23]	Sedlarikova L, Gromesova B, Kubaczkova V, et al. Deregulated expression of long non-coding RNA UCA1 in multiple myeloma[J]. Eur J Haematol, 2017, 99(3):223-233. doi: 10.1111/ejh.12908
[24]	Yang C, Li X, Wang Y, et al. Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3- K dependent pathway in bladder carcinoma cells[J]. Gene, 2012, 496(1):8-16. doi: 10.1016/j.gene.2012.01.012
[25]	Sun CC, Zhang L, Li G, et al. The lncRNA PDIA3P interacts with miR-185- 5p to modulate oral squamous cell carcinoma progression by targeting cyclin D2[J]. Mol Ther Nucleic Acids, 2017, (9):100-110. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626923/
[26]	Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13[J]. Blood, 2009, 114(3):522-525. doi: 10.1182/blood-2008-12-193458
[27]	Yang X, Ye H, He M, et al. LncRNA PDIA3P interacts with c-Myc to regulate cell proliferation via induction of pentose phosphate pathway in multiple myeloma[J]. Biochem Biophys Res Commun, 2018, 498(1): 207-213. doi: 10.1016/j.bbrc.2018.02.211
[28]	Zhou CC, Yang F, Yuan SX, et al. Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma[J]. Hepatology, 2016, 63(3):850-863. doi: 10.1002/hep.28393
[29]	Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the intergroupe francophone du myelome[J]. Blood, 2007, 109(8):3489-3495. doi: 10.1182/blood-2006-08-040410
[30]	Xiao G, Li Y, Wang Y, et al. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity[J]. Exp Cell Res, 2018, 370(2):254-263. doi: 10.1016/j.yexcr.2018.06.026
[31]	Naemura M, Kuroki M, Tsunoda T, et al. The long noncoding RNA OIP5- AS1 is involved in the regulation of cell proliferation[J]. Anticancer Res, 2018, 38(1):77-81. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=4c3b10acc0c9e0708a285f49de039ed0
[32]	Yang N, Chen J, Zhang H, et al. LncRNA OIP5- AS1 loss- induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma[J]. Cell Death Dis, 2017, 8(8):e2975. doi: 10.1038/cddis.2017.358
[33]	Zhang Z, Liu F, Yang F, et al. Kockdown of OIP5-AS1 expression inhibits proliferation, metastasis and EMT progress in hepatoblastoma cells through up-regulating miR-186a-5p and down-regulating ZEB1[J]. Biomed Pharmacother, 2018, (101):14-23. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=3f36b05d1516124d1a49a7cf3b98bb5e
[34]	Sun H, Wang G, Peng Y, et al. H19 lncRNA mediates 17beta-estradiolinduced cell proliferation in MCF-7 breast cancer cells[J]. Oncol Rep, 2015, 33(6):3045-3052. doi: 10.3892/or.2015.3899
[35]	Pan Y, Zhang Y, Liu W, et al. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR- 29b-3p[J]. Cell Death Dis, 2019, 10(2):106. doi: 10.1038/s41419-018-1219-0
[36]	Corrado C, Costa V, Giavaresi G, et al. Long non coding RNA H19: a new player in hypoxia-induced multiple myeloma cell dissemination[J]. Int J Mol Sci, 2019, 20(4):199-205. https://www.onacademic.com/detail/journal_1000041695538599_9b2d.html
[37]	Quan LJ, Wang WJ. FEZF1-AS1 functions as an oncogenic lncRNA in retinoblastoma[J]. Biosci Rep, 2019, 35(3):3357-3362.
[38]	Li QY, Chen L, Hu N, et al. Long non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma via miR-610/Akt3 axis[J]. Biomed Pharmacother, 2018, (103):1727-1732. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=1c3b984d3f71787674f6b676fbb3a15d
[39]	Yang M, Zhang L, Wang X, et al. Down-regulation of miR-203a by lncRNA PVT1 in multiple myeloma promotes cell proliferation[J]. Arch Med Sci, AMS, 2018, 14(6):1333-1339. doi: 10.5114/aoms.2018.73975
[40]	Dong H, Jiang S, Fu Y, et al. Upregulation of lncRNA NR_046683 serves as a prognostic biomarker and potential drug target for multiple myeloma[J]. Front Pharmacol, 2019, (10):45-49.